{"id":"NCT00550680","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Mircera for the Maintenance Treatment of Participants With Chronic Renal Anemia","officialTitle":"A Single Arm, Open Label Study to Assess the Efficacy, Safety, and Tolerability of Once-Monthly Administration of Intravenous C.E.R.A. for the Maintenance of Haemoglobin Levels in Dialysis Patients With Chronic Renal Anaemia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-01","primaryCompletion":"2009-09","completion":"2009-09","firstPosted":"2007-10-30","resultsPosted":"2016-03-30","lastUpdate":"2016-03-30"},"enrollment":208,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Renal Anemia"],"interventions":[{"type":"DRUG","name":"Methoxy polyethylene glycol-epoetin beta","otherNames":["Mircera/CERA"]}],"arms":[{"label":"Mircera in Renal Anemia","type":"EXPERIMENTAL"}],"summary":"This single-arm study will assess the efficacy and safety of intravenous (IV) Mircera when administered for the maintenance of hemoglobin (Hb) levels in participants with chronic renal anemia. Individuals currently receiving maintenance treatment with epoetin alfa or darbepoetin alfa will receive monthly injections of Mircera, with the starting dose (120, 200, or 360 micrograms \\[mcg\\] IV injection) derived from the dose of epoetin alfa or darbepoetin alfa they were receiving in the week preceding study start.","primaryOutcome":{"measure":"Percentage of Participants Who Maintained Average Hb Within Plus/Minus (Â±) 1 g/dL of Reference Hb and Within Target Range During the Efficacy Evaluation Period (EEP)","timeFrame":"Weeks -4, -3, -2, -1,and 0; pre-dose (0 hours) during Weeks 18, 20, 22, and 24","effectByArm":[{"arm":"Mircera in Renal Anemia","deltaMin":53.7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":24,"countries":["Greece"]},"refs":{"pmids":["26965694"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":34,"n":188},"commonTop":["Hypertension"]}}